# Transcranial random noise stimulation for the acute treatment of depression: a randomized controlled trial

5	Stevan Nikolin <sup>1,2</sup> ,	Angelo Alonzo <sup>1,2</sup>	Donel Martin <sup>1,2</sup> ,	Veronica (	Gálvez <sup>1,3</sup> , S	Sara Buten <sup>1,4</sup> ,
---	---------------------------------	------------------------------	-------------------------------	------------	---------------------------	-----------------------------

6 Rohan Taylor<sup>1,5</sup>, James Goldstein<sup>6</sup>, Cristal Oxley<sup>7</sup>, Dusan Hadzi-Pavlovic<sup>1</sup>, Colleen K.

### Loo<sup>1,2,8</sup>

- 8 <sup>1</sup> School of Psychiatry, University of New South Wales, Sydney, Australia
- 9 <sup>2</sup> Black Dog Institute, Sydney, Australia

4

7

- 10 <sup>3</sup> Mental Health Department, Parc Taulí University Hospital, Institut d'Investigació I
- 11 Innovació Sanitària Parc Taulí (I3PT), Barcelona, Spain
- <sup>4</sup> Prince of Wales Hospital, Sydney, Australia
- 13 <sup>5</sup> Concord Centre for Mental Health, Concord, Australia
- 14 <sup>6</sup> Currumbin Clinic, Currumbin, Australia
- <sup>15</sup> <sup>7</sup> Department of Child and Adolescent Psychiatry, Michael Rutter Centre South London and
- 16 Maudsley NHS Foundation Trust, UK
- 17 <sup>8</sup> St. George Hospital, Sydney, Australia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 18 Abstract

### 19 Background

20 Transcranial electrical stimulation has broad potential as a treatment for depression.

21 Transcranial random noise stimulation (tRNS), which delivers randomly fluctuating current

22 intensities, may have greater cortical excitatory effects compared to other forms of

23 transcranial electrical stimulation. We therefore aimed to investigate the antidepressant

efficacy of tRNS.

### 25 Methods

Depressed participants were randomly assigned by computer number generator to receive 20 sessions of either active or sham tRNS over four weeks in a double-blinded, parallel group randomized-controlled trial. tRNS was delivered for 30mins with a direct current offset of 2mA and a random noise range of 2mA. Primary analyses assessed changes in depression severity using the Montgomery-Asperg Depression Rating Scale (MADRS). Neuroplasticity, neuropsychological, and safety outcomes were analysed as secondary measures.

### 32 Results

33 69 participants were randomised, of which three discontinued treatment early leaving 66

34 (sham n = 34, active n = 32) for per-protocol analysis. Depression severity scores reduced in

both groups (MADRS reduction in sham = 7.0 [95%CI 5.0-8.9]; and active = 5.2 [95%CI

36 3.2-7.3]). However, there were no differences between active and sham groups in the

37 reduction of depressive symptoms, or the number of participants meeting response (sham =

14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%). Erythema,

39 paraesthesia, fatigue, and dizziness/light-headedness occurred more frequently in the active

40 tRNS group. Neuroplasticity, neuropsychological and acute cognitive effects were

41 comparable between groups.

### 42 **Conclusion**

- 43 Our results do not support the use of tRNS with the current stimulation parameters as a
- 44 therapeutic intervention for the treatment of depression.

### 45 Clinical Trial Registration:

- 46 Clinical registration was obtained on the 15<sup>th</sup> February 2013 from clinicaltrials.gov
- 47 (NCT01792414) after recruitment of the first study participant on the 30<sup>th</sup> January 2013, but
- 48 prior to the participant's completion of the four week sham-controlled phase of the trial. All
- 49 remaining participants were recruited following clinical registration.

### 50 **Funding:** NHMRC project grant APP1051423

51

## 52 Keywords:

- 53 Transcranial Random Noise Stimulation
- Electric Stimulation Therapy [E02.331]
- Depression [F01.145.126.350]
- Randomized Controlled Trial [V03.175.250.500.500]

# 57 Introduction

58 Although there are a number of established treatments for depression, a sizeable 59 proportion of patients still fail to adequately respond, with a conservative estimate of approximately one-third of these not reaching remission even after four trials of different 60 61 antidepressant medication classes (Rush et al., 2006). In addition, many patients fail to complete a course of antidepressants due to side effects (Trivedi et al., 2006). While 62 63 electroconvulsive therapy (ECT) remains the most effective treatment, with response rates of 64 up to 70% (Hag et al., 2015), treatment uptake and adherence can be limited by patient 65 concerns over possible cognitive side effects and the need for general anaesthetic. Thus, there 66 has been interest in the development of novel, non-convulsive brain stimulation techniques 67 that are well-tolerated and have a benign side effect profile, such as transcranial electrical stimulation. These neuromodulatory techniques could have the greatest potential for 68 69 translation into widespread clinical use, being relatively inexpensive, easy to use, portable, 70 and safe (Bikson et al., 2016; Nikolin et al., 2017). Here we report an investigation of the 71 efficacy of one such technique, transcranial random noise stimulation (tRNS), for the treatment of depression. 72

73 Transcranial electrical stimulation involves applying a weak electrical current to 74 cerebral tissue via scalp electrodes, resulting in modulation of neuronal membrane potentials 75 and spontaneous firing rates (Nitsche et al., 2008) that can lead to long term changes in 76 cortical excitability and plasticity (Nitsche and Paulus, 2001; Player et al., 2014a). Applying 77 a direct current between the electrodes, referred to as transcranial direct current stimulation (tDCS), has been demonstrated to have antidepressant effects in clinical trials (Loo et al., 78 79 2012a; Brunoni et al., 2013b; Brunoni et al., 2017). Recent meta-analyses of randomised, 80 sham-controlled trials have found tDCS to be more effective than sham stimulation, with

significantly higher remission and response rates as well as a greater reduction in depressive
symptoms (Brunoni et al., 2016; Mutz et al., 2018). As depression has increasingly been
conceptualised as a disorder underpinned by disrupted neuroplasticity (Pittenger and Duman,
2008; Liu et al., 2017), cumulative changes to synaptic functioning may underlie the
therapeutic effects observed in clinical trials of tDCS (Szymkowicz et al., 2016). Modifying
stimulation parameters to enhance cortical excitability effects may therefore present a
pathway to increase treatment efficacy.

88 tRNS is a more recently developed transcranial electrical stimulation technique that 89 involves randomly fluctuating current intensities over a broad frequency spectrum (between 90 0.1 to 640 Hz). There is some evidence that tRNS has comparable, if not greater, cortical 91 excitatory effects as compared to tDCS (Moliadze et al., 2014; Ho et al., 2015b; Inukai et al., 92 2016). A single session of 10 minutes of 1 milliampere (mA) tRNS to the motor cortex has 93 been found to produce a greater increase in cortical excitability than tDCS, lasting up to 60 94 minutes beyond the stimulation period (Moliadze et al., 2014; Inukai et al., 2016), although 95 tDCS may lead to a longer period of excitation of at least 90 minutes post-stimulation 96 (Moliadze et al., 2014). tRNS may also be applied with a direct current offset so that the 97 stimulation incorporates neuromodulatory features of tDCS, in addition to limiting 98 homeostatic responses via randomly fluctuating current intensities. Results from Ho et al. 99 (2015b) suggest that tRNS with a direct current offset may be more effective in increasing 100 motor cortical excitability than the more common application of tRNS without an offset. 101 There has been a burgeoning growth in recent years of studies investigating the 102 application of tRNS to enhance sensory processing (Ghin et al., 2018; Rufener et al., 2018; 103 Contemori et al., 2019), motor performance (Abe et al., 2019; Jooss et al., 2019), and 104 cognition (Snowball et al., 2013; Popescu et al., 2016; Mammarella et al., 2017; Shalev et al.,

105 2018; Tyler et al., 2018) in healthy participants with largely promising results. To date,

106 however, few studies have examined the effectiveness of tRNS for clinical/therapeutic uses, 107 with such studies typically characterised by small sample sizes and/or varying efficacy (Chan et al., 2012; Haesebaert et al., 2014; Palm et al., 2016a; Hayward et al., 2017; Kreuzer et al., 108 2017; Salemi et al., 2019). Regarding the effects of tRNS on mood, there is currently only 109 110 one report involving treatment of major depressive disorder (MDD). Chan et al. (2012) 111 reported a case of a patient diagnosed with MDD who had responded to two trials of tDCS (2 112 mA, 20 minutes, 15 sessions over 3 weeks) prior to trialling a 4-week course of open-label 113 tRNS (2 mA range with 1 mA direct current offset, 20 sessions lasting 20 minutes each). It was found that by the 15<sup>th</sup> session, there was a 63% reduction from baseline in the severity of 114 115 depressive symptoms, compared with a reduction of 31% and 25% at the end of the acute 116 treatment phase in the two prior trials of tDCS. For all three trials, depression scores at 117 baseline were similar but the patient reported faster improvement with tRNS and lesser skin 118 sensations compared to tDCS. Given this encouraging case report finding, and the potential 119 theoretical advantages of tRNS relative to tDCS, further investigation of the antidepressant 120 effects of tRNS is warranted.

The primary aim of this study, therefore, was to conduct the first randomised, sham-121 122 controlled trial of tRNS in depression. It was hypothesised that tRNS would have significant 123 antidepressant efficacy compared with a sham control over a 4-week treatment phase. A 124 secondary aim of this study was to examine whether antidepressant effects of tRNS were 125 mediated by restoration of brain neuroplasticity. We hypothesised that antidepressant 126 response to tRNS would be associated with increased brain plasticity, given prior findings of 127 reduced neuroplasticity in depressed individuals compared to healthy matched controls 128 (Player et al., 2013), and findings suggesting a normalisation of neuroplasticity following 129 antidepressant treatment using tDCS (Player et al., 2014b). Lastly, as this is the first treatment trial of tRNS for depression, a comprehensive neuropsychological test battery was designed 130

specifically to be sensitive to symptom changes, measure any adverse cognitive effects, andto assess any potential acute cognitive enhancing effects.

# **133 Materials and Methods**

### 134 Trial design

135 The main study phase used a double-blinded, parallel, randomized, sham-controlled 136 design. Participants were assigned by a computer-generated random number sequence to one 137 of two groups: active tRNS or sham tRNS. Randomization was stratified according to 138 whether participants were diagnosed with unipolar or bipolar depression. Participants were 139 required to attend a total of 20 tRNS sessions over four weeks conducted on consecutive 140 weekdays during the sham-controlled phase. Participants who missed five or more sessions 141 during the sham-controlled phase were withdrawn from the trial, and were excluded from 142 analyses using a per-protocol approach. All participants were offered an additional 20 143 sessions of open-label active tRNS over four weeks, also administered every weekday. After 144 treatment in the acute daily treatment phases, participants entered a taper phase during which they received once weekly tRNS treatment for four weeks with the final taper session 145 146 coinciding with a 1-month follow-up visit. Participants were then followed up at 3, 6 and 9 147 months. Participants and raters were blinded to tRNS condition and blinding was maintained 148 until the study was completed and the dataset locked.

Mood, neuroplasticity, and neuropsychological function were assessed at the intervals shown in Supplementary Table S1. Adequacy of blinding to treatment was assessed at the end of the sham-controlled phase by asking participants and raters to guess the tRNS condition administered during the first four weeks of treatment. To investigate whether treatment expectations may be a predictor of response, participants completed the Treatment

154 Expectancy Questionnaire (TEQ; see Supplementary Figure S1) at baseline before the first
155 tRNS session.

156 The study was powered for the primary aim of testing efficacy over the sham-157 controlled phase. From pilot data, it was assumed that tRNS would be at least as effective as 158 tDCS when tested in a sham-controlled trial, given that sampling criteria were very similar. 159 Means and standard deviations of the active and sham treatment groups from our previous, 160 sham-controlled, 3-week trial of tDCS (Loo et al., 2012b) were used, with outcomes 161 extrapolated for a 4-week comparison period. This resulted in an effect size of Cohen's d =162 0.7. For 80% power and  $\alpha = 0.05$ , a sample of 33 subjects per group was required to demonstrate a difference between active and sham treatment. 163 164 165 **Participants** 166 At study entry, participants were at least 18 years old; in a current major depressive 167 episode (as part of a MDD or Bipolar Disorder) of a minimum four weeks duration, defined 168 according to Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text 169 revision; DSM-IV-TR) criteria and established using the Mini International Neuropsychiatric 170 Interview (MINI; Version 5.0.0) (Sheehan et al., 1998) and study clinician assessment; and 171 had a total score of at least 20 on the Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979). Participants were free of antidepressant 172 173 medications, or continued on stable doses of antidepressant medications to which they had 174 failed to respond after an adequate course of treatment, with dosage unchanged for at least 175 four weeks prior to study entry. Bipolar participants were required to be on a mood stabilizer 176 medication (e.g. lithium) as prophylaxis against treatment-emergent mania or hypomania for 177 the duration of the study.

178	Exclusion criteria included: psychotic disorder as per DSM-IV-TR; drug or alcohol
179	abuse or dependence within 12 months of study entry; inadequate response to ECT in the
180	current depressive episode; current benzodiazepine medication; rapid clinical response
181	required (e.g., due to high suicide risk); clinically defined neurological disorder or insult;
182	metal in the cranium; skull defects; skin lesions on the scalp at electrode sites; or pregnancy.
183	The study was approved by the human research ethics committee of the University of
184	New South Wales and was conducted at the Black Dog Institute in Sydney, Australia.
185	Participants provided written informed consent for this study. Recruitment began in January
186	2013 and the last follow-up was conducted in 2017. The study was registered with the
187	ClinicalTrials.gov website (Identifier: NCT01792414).
188	
189	Transcranial random noise stimulation
190	A DC-Stimulator Plus device (NeuroConn GmbH, Germany) applied high frequency
191	tRNS (100-640 Hz) via two 7 x 5 cm saline-soaked sponge-covered electrodes held in
192	position by a headband. Active tRNS was administered for 30 mins per session with a range
193	of 2 mA and an offset of 2 mA. The anode was placed over F3 (as per the 10-20 international
194	electroencephalogram system), corresponding to the left dorsolateral prefrontal cortex
195	(LDLPFC), and the cathode over F8. For sham stimulation, the current was ramped up over
196	10 s, left on for 30 s, then gradually ramped down over 10 s, so that both treatment groups
197	experienced an initial tingling sensation. The tRNS machine was then left on until the end of
198	the session to preserve blinding. This sham procedure resulted in adequate blinding for tDCS
199	in previous trials (e.g., (Loo et al., 2010; Loo et al., 2012b)), and was therefore expected to be
200	sufficient for tRNS, which produces milder skin sensations compared to tDCS (Ambrus et al.,
201	2010). Participants were comfortably seated at rest and did not engage in any particular tasks
202	during stimulation.

### 203

# 204 Clinical outcome measures

205	The primary outcome measure for comparing active and sham tRNS was the MADRS,
206	which was administered by trained raters with established inter-rater reliability (intraclass
207	correlation coefficient $> 0.7$ ). Secondary measures were the Clinician Global Impression –
208	Improvement (CGI-I) (Guy, 1976), Beck Depression Inventory (BDI-II) (Beck et al., 1996) and
209	Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form (Q-LES-SF)
210	(Endicott et al., 1993) scales.
211	
212	Neuroplasticity outcome measures
213	As an optional study offered to participants in the main tRNS trial, a paired
214	associative stimulation (PAS) paradigm previously described in Player et al. (2012) was used
215	to assess the effects of tRNS on neuroplasticity. The PAS testing was conducted at baseline
216	before the first tRNS session, and again after completion of the sham-controlled and open-
217	label phases. Briefly, the PAS paradigm involves measuring motor evoked potentials (MEPs)
218	following single-pulse transcranial magnetic stimulation (TMS) via electromyography
219	(EMG) before and after applying a stimulation protocol (i.e., PAS) to the motor cortex to
220	assess changes in motor cortical excitability (see the Supplementary Material for a detailed
221	description of PAS methodology).
222	
223	Neuropsychological outcome measures
224	The following neuropsychological battery was administered to comprehensively
225	assess cognitive function: California Verbal Learning Test-II (CVLT-II) (Delis et al., 2000) -
226	verbal learning and memory; Ruff 2 & 7 (Ruff and Allen, 1996) – attention processes;

227 Wechsler Adult Intelligence Scale-IV edition (WAIS-IV) Digit Span subtest (Wechsler,

228 2008) – simple auditory attention and working memory; Symbol Digit Modality Test 229 (SDMT) (Smith, 1991) – psychomotor processing speed; Delis-Kaplan Executive Function 230 System (D-KEFS) Verbal Fluency test (Delis et al., 2001) – phonemic fluency, semantic fluency, cognitive flexibility; and Cognitive Failures Questionnaire (Broadbent et al., 1982) -231 232 subjective cognitive functioning. Alternative versions of the CVLT-II, D-KEFS Verbal Fluency, and SDMT were used to minimize practice effects. In addition, computer 233 234 administered cognitive tests were used to assess safety and acute effects. A simple reaction 235 time test, in which participants were instructed to press a space bar as soon as they saw a 236 cross appear in the middle of a computer screen, was administered immediately before and 237 after the first tRNS session. An Emotion Recognition Task (Montagne et al., 2007), which 238 assessed recognition of six basic facial emotions, was also administered after the first tRNS 239 session. 240

### 241 Physical adverse events

As an additional safety outcome measure, physical adverse events were assessed each session using a tRNS Side Effects Questionnaire (Supplementary Figure S2), adapted from Brunoni et al. (2011), which collected information regarding the type of adverse event, its severity, and its causality.

246

### 247 Statistical Analyses

All statistical analyses were conducted using SPSS software (IBM SPSS Statistics 25 for Windows; SPSS Inc.). Outcome measures were analysed for change over the shamcontrolled phase using a mixed-effects repeated measures (MERM) model with a restricted number of covariates. Time was entered as a repeated measures factor with an unstructured covariance matrix, tRNS Condition (active or sham) was a between-subjects factor, and

253 subjects were included as a random effect. For mood and quality of life outcomes, covariates 254 were selected based on prior reports of their significant effect on antidepressant response to 255 transcranial electrical stimulation; these included treatment resistance (Brunoni et al., 2016) (assessed by the Maudsley Staging Method (Fekadu et al., 2009)), and presence of concurrent 256 257 antidepressant medications (Brunoni et al., 2013a; Brunoni et al., 2013c). A MERM model 258 was similarly used for neuropsychological outcomes, with MADRS mood scores at the 259 respective time points included as a covariate. Acute cognitive effects following the first 260 session were examined using a two-way repeated measure analysis of variance 261 (RMANOVA), with factors of tRNS Condition and Time (pre and post session 1). For the 262 Emotion Recognition Task, a multivariate ANOVA (MANOVA) was conducted with the 263 between-subject factor of tRNS Condition. 264 Additional MERM analyses were conducted for the primary outcome measure 265 (MADRS). Baseline scores on the TEQ were added as a covariate to the MERM analysis to 266 test whether treatment expectations modified mood outcomes. To assess whether medication 267 use affected outcomes, each medication class (antidepressants, benzodiazepines, 268 antipsychotics, lithium and anticonvulsants) was entered as the only covariate in separate 269 MERM analyses. 270 The number of responders (defined as a reduction in MADRS total score of  $\geq 50\%$ 271 from baseline) and remitters (defined as a final MADRS total score < 10) at the end of the 272 sham-controlled phase were compared between active and sham tRNS groups using a 273 Fisher's exact test. 274 The association between participant or rater guesses (active or sham) and the 275 participant's assigned tRNS condition (active or sham) was tested using a Pearson Chi-square 276 test with Yates' continuity correction. Cohen's kappa statistic was used to assess agreement

between participant and rater guesses.

278 Statistical tests were two-tailed and significance was set at p < 0.05.

279

# 280 **Results**

- 281 A total of 69 participants met inclusion criteria and were randomized to receive either active
- 282 or sham tRNS during the sham-controlled phase (see the CONSORT flow diagram,
- 283 Supplementary Figure S3). A total of 66 participants (sham: 34, active: 32) completed the
- sham-controlled phase and were analysed using a per-protocol approach. Table 1 shows
- 285 demographic and clinical characteristics for active and sham tRNS groups at baseline.

### **Table 1. Comparison of demographic and clinical characteristics at baseline.**

	Sham	Active
n	34	32
Medications (yes/no)		
Any concurrent medication	27/7	22/10
Antidepressant	23/11	20/12
Lithium	1/33	2/30
Benzodiazepine*	2/32	2/30
Antipsychotic	6/28	4/28
Anticonvulsant	5/29	1/31
Clincial and demographic variables (m, SD)		
Gender (m/f)	19/15	17/15
Melancholic (yes/no)	19/9	12/12
MDD/BP1/BP2	30/3/1	30/0/2
Age (years)	48.8 (12.3)	47.5 (12.0)
Age at onset (years)	27.0 (9.6)	27.5 (9.6)
Duration of current episode (months)	24.4 (32.2)	37.2 (48.0)
Duration of previous episodes (months)	65.9 (65.8)	88.5 (93.6)
Antidepressants failed current episode	2.1 (1.7)	2.6 (2.9)
Total lifetime failed antidepressants	4.0 (3.0)	5.0 (5.1)
Maudsley Staging score	7.3 (2.1)	6.5 (1.9)
Baseline MADRS score	29.5 (4.6)	30.1 (5.0)
Baseline BDI-II score	33.8 (9.1)	34.1 (9.4)
Baseline CGI-S score	4.4 (0.6)	4.4 (0.6)
Baseline Q-LES-SF score	32.8 (10.5)	34.9 (11.2)
Baseline TEQ score	24.5 (7.6)	24.1 (7.1)

<sup>287 \*</sup>Participants were required to cease benzodiazepine medication use prior to commencing the trial.

MDD: Major depressive disorder. BP1/BP2: Bipolar I and bipolar II disorder. MADRS: Montgomery-Asberg Depression
 Rating Scale. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. BDI-II: Beck Depression
 Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale ranked from 1-normal to 7 extremely ill. TEQ: Treatment Expectancy Questionnaire.

292

### 293 Clinical outcome measures

294 Table 2 shows the results for all MERM analyses of mood and quality of life outcome 295 measures during the sham-controlled phase. MERM analysis of MADRS scores showed a 296 significant effect of Time (p < 0.001). There was, however, no effect of tRNS Condition (p =297 0.630), and no significant Time  $\times$  Condition interaction (p = 0.445; see Figure 1). Results 298 from intention-to-treat analyses are also reported for all planned outcomes in Supplementary 299 Table S2, in accordance with CONSORT guidelines for parallel group randomised control 300 trials (Schulz et al., 2010). Repeating the analysis while incorporating scores from the 301 Treatment Expectations Questionnaire as an additional covariate did not modify outcomes. 302 Concurrent medications did not significantly affect outcomes when entered as covariates in 303 separate MERM analyses (see Supplementary Table S3). Supplementary Table S4 shows 304 results from MERM analyses of all outcome measures acquired during the acute daily 305 treatment phases combined (i.e. both sham-controlled and open-label phases). Supplementary 306 Figure S4 shows graphs of mood and quality of life measures for all time-points up to the 9-307 month follow-up assessment. 308 One participant in the active tRNS group (3.1%), and five participants receiving sham


tRNS (14.7%), were considered treatment responders after completion of the sham-controlled
phase (i.e. following 20 sessions of tRNS). Only two participants met the remission criterion,

both in the sham tRNS condition (5.9%). Fisher's exact tests revealed no statistically

312 significant differences between active and sham tRNS conditions for response (p = 0.198)

313 and remission (p = 0.493) rates.

314





316

**Figure 1. Mood scores.** Graph showing MADRS scores (estimated marginal means ±

317 SD) across rating time points, including the sham-controlled phase (from baseline to 4-

318 weeks), open-label phase (from 4 - 8 weeks), and 1-month follow-up assessment following

319 the final taper session. Dotted lines indicate sham tRNS sessions delivered during the sham-

320 controlled phase.

321 Table 2. Mood and quality of life outcome measures. Estimated marginal means and results from MERM analyses during the

322 sham-controlled phase. MERM analyses were performed including the following covariates: Maudsley staging method total score as a

		Base	eline	We	ek 2	We	ek 4	Con	dition	Т	ime		me × dition
Λ	lood Assessments (m, SEM)	Sham	Active	Sham	Active	Sham	Active	F	р	F	р	F	р
	MADRS	29.1 (0.8)	28.9 (0.8)	24.4 (1.0)	24.8 (1.1)	22.1 (1.2)	23.7 (1.3)	0.24	0.630	41.73	<0.001	0.82	0.445
	BDI-II	32.6 (1.7)	33.2 (1.8)	25.2 (1.9)	27.2 (2.0)	22.1 (1.9)	24.9 (2.0)	0.72	0.399	24.56	<0.001	0.46	0.762
	CGI-I	-	-	3.5 (0.1)	3.6 (0.1)	3.1 (0.1)	3.4 (0.1)	2.24	0.140	12.69	<0.001	2.10	0.153
	Q-LES-SF	32.4 (1.9)	36.0 (2.1)	-	-	43.5 (2.8)	43.9 (2.9)	0.45	0.503	31.67	<0.001	0.84	0.362

323 measure of treatment resistance, and antidepressant use.

324 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale 325 ranked from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form. m: Mean. SEM: Standard error of measure.

# 327 Neuroplasticity outcome measures

328	A total of 44 participants (sham: 25, active: 19) completed the optional PAS study to
329	assess changes in motor cortical excitability. A MERM analysis found no significant effects
330	of Time ( $p = 0.209$ ) or Condition ( $p = 0.780$ ), and no significant Time × Condition interaction
331	( $p = 0.570$ ; see Table 3, and Supplementary Figure S5). Furthermore, change in MADRS
332	scores did not correlate with changes in MEP amplitudes from baseline to the end of the
333	sham-controlled phase (r = -0.02, $p = 0.905$ ; Supplementary Figure S6).
334	
335	Neuropsychological outcomes

336 Neuropsychological outcomes during the sham-controlled phase are shown in Table 3. There

337 were no significant main effects of Time, and no significant Time × Condition interaction

338 effects for all neuropsychological measures.

339 Table 3. Neuroplasticity and neuropsychological outcome measures. Estimated marginal means and results from MERM analyses340 during the sham-controlled phase. The neuroplasticity MERM analysis were performed including the following covariates: Maudsley staging341 parameters total score as a measure of treatment resistance, and antidepressant use. Neuropsychological MERM analyses were performed using342 MADRS scores as a covariate.

Baseli		line Week 4			Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	F	р	F	р	F	р
Neuroplasticity Assessment (m, SEM)										
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	1.31 (0.09)	1.40 (0.10)	0.08	0.780	1.63	0.209	0.33	0.570
Neuropsychological Assessments (m, SEM)										
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.8)	48.7 (2.2)	46.3 (2.3)	49.7 (2.2)	2.12	0.148	0.12	0.734	0.01	0.913
CVLT-II: Long delay free recall z-score	-0.41 (0.21)	0.03 (0.22)	-0.64 (0.22)	-0.38 (0.21)	2.69	0.104	1.85	0.176	0.20	0.653
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.5 (0.7)	10.9 (0.7)	11.9 (0.7)	0.97	0.327	0.01	0.945	0.32	0.575
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	9.8 (0.8)	11.8 (0.8)	2.84	0.094	0.05	0.828	0.80	0.372
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.1 (0.6)	9.6 (0.6)	10.6 (0.6)	3.36	0.069	0.50	0.480	0.02	0.888
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	49.9 (1.9)	51.3 (1.9)	53.6 (1.8)	1.66	0.200	3.45	0.066	0.01	0.946
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.6 (2.4)	50.4 (2.4)	48.7 (2.3)	1.02	0.316	0.34	0.561	0.08	0.779
SDMT: Total correct z-score	-0.31 (0.18)	0.25 (0.18)	-0.02 (0.19)	0.41 (0.18)	7.78	0.006	1.32	0.254	0.15	0.703
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.6)	10.5 (0.6)	12.6 (0.5)	13.00	<0.001	2.57	0.112	0.12	0.732
CFQ: Total score	50.0 (2.2)	46.8 (2.3)	49.9 (2.3)	50.0 (2.2)	0.52	0.474	0.40	0.528	0.57	0.451

PAS: Paired associative stimulation. MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test.
 D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measure.

### 346 Acute cognitive effects

For reaction time, the main effects of Time (p = 0.404), Condition (p = 0.992), and the Time × Condition interaction effect (p = 0.949) were not statistically significant. Further, for the Emotion Recognition Task the main effect of tRNS Condition was not statistically significant (p = 0.347).

### 351 Physical adverse events

Adverse events occurring during the sham-controlled and open-label phases of the trial are presented in Table 4. Side-effects were transient and mild-to-moderate in severity. Pearson Chi-square tests revealed significantly more instances of erythema (skin redness; p < 0.001), paraesthesia (tingling, burning, and itching sensations; p < 0.001), fatigue (p = 0.006), and dizziness/light-headedness (p = 0.002) following active tRNS as compared to sham tRNS sessions.

557 5655

358

Table 4. Physical adverse event frequency. Adverse events are sorted according to
 overall likelihood of occurrence, with events most likely to occur listed first. Differences in
 frequency of adverse event occurrence during the sham-controlled phase was tested using
 Pearson Chi-square tests with Yates' continuity correction.

		Sham-controlled phase						abel phase
	Sham (646 sessions)		Active (650 sessions)		Pearson Chi-square		Active (1161 session	
	n	%	n	%	χ2	<i>p</i> -value	n	%
Erythema	129	20.0	454	69.8	323.67	<0.001	781	67.3
Tingling	126	19.5	332	51.1	139.96	<0.001	623	53.7
Burning	15	2.3	251	38.6	214.14	<0.001	370	31.9
Itching	40	6.2	97	14.9	25.21	<0.001	170	14.6
Fatigue	33	5.1	60	9.2	7.66	0.006	75	6.5
Headache	43	6.7	30	4.6	2.17	0.141	31	2.7
Dizziness/light-headedness	10	1.5	31	4.8	9.95	0.002	48	4.1
Nausea	7	1.1	15	2.3	2.22	0.136	36	3.1
Scalp Discomfort	7	1.1	9	1.4	0.06	0.811	10	0.9
Other	14	2.2	26	4.0	3.05	0.081	58	5.0

### 364 Blinding integrity

365 Participants were asked to guess their treatment condition at the end of the doubleblinded sham-controlled phase. 75% of participants in the sham condition correctly guessed 366 they received sham tRNS, and 55% of participants in the active condition correctly guessed 367 368 they had received active tRNS. A Pearson Chi-square test of participant guesses was significant ( $\chi^2 = 4.68$ ; p = 0.031), suggesting that participants were not adequately blinded to 369 their treatment condition. To determine whether participant guesses of treatment condition 370 371 may have influenced mood outcomes, we performed a post-hoc simple linear regression 372 analysis; percent change in MADRS score over the 4-week sham-controlled phase was 373 selected as the dependent variable, and participant guess (active, sham) as the independent variable. This analysis was not statistically significant ( $R^2 = 0.023$ , F = 1.43, p = 0.237). 374 375 Blinded study raters were similarly asked to guess participants' treatment condition at 376 the end of the sham-controlled phase. Raters correctly guessed that participants had received 377 sham tRNS 56% of the time, and active tRNS 31% of the time. A Pearson Chi-square test found this difference not to be statistically significant ( $\chi^2 = 0.492$ ; p = 0.483). Furthermore, 378 379 Cohen's kappa showed no agreement between participant and rater guesses ( $\kappa = 0.134$ ; p = 380 0.329).

# 381 Discussion

398

399

382 Here we report the results of the first randomized control trial to examine the efficacy of tRNS for the treatment of depression. Although there was a significant reduction of 383 384 depressive symptoms over the duration of the study period, there was no difference in the rate 385 of improvement between sham and active tRNS conditions. Further, there was no significant 386 effect of tRNS on neuroplasticity measures in the subset of participants that completed the 387 PAS paradigm, suggesting that stimulation did not increase global cortical excitability. tRNS 388 was found to be safe with no adverse acute cognitive, neuropsychological or severe phyisical 389 side effects. However, tRNS resulted in a higher incidence rate of skin redness (erythema) 390 and paraesthesia (tingling, itching, and burning sensations) in the active condition, as well as 391 fatigue and dizziness/light-headedness, which occurred in fewer than 10% of sessions. 392 Nevertheless, the stimulation protocol was well-tolerated with only one participant dropping-393 out due to adverse effects, which were not conclusively associated with tRNS. 394 The results of this study do not support the use of tRNS with the current stimulation 395 parameters as a therapeutic intervention for the treatment of depression. Despite encouraging 396 initial evidence of significant reductions in depression scores in patients with fibromyalgia

397 (Curatolo et al., 2017), and a case report of improvement in MDD (Chan et al., 2012), mood

and quality of life outcomes in the active tRNS group were no different from the placebo-

controlled response in the sham group at all time-points. The size of reductions in depressive

400 symptoms observed in both conditions of the present study is broadly similar to the sham

401 condition of previous trials of tDCS for depression (Blumberger et al., 2012; Loo et al.,

402 2012a; Palm et al., 2012; Brunoni et al., 2013b; Bennabi et al., 2015). Of these previous

403 tDCS trials, our study design was most similar to a recent international multisite investigation

404 conducted by our group, which observed improvements in depression scores of 27.8% and

405 22.3% in sham and active tDCS conditions, respectively, as compared to 24.1% and 18.0% in

406 sham and active tRNS conditions (Loo et al., 2018). We recruited participants using 407 analogous inclusion/exclusion criteria, participant demographic and clinical characteristics, 408 and adopted comparable stimulation parameters, at least in terms of treatment duration (30 409 minutes), session number and frequency (20 daily weekday sessions), and direct current 410 intensity (2 mA direct current offset in the present study vs a marginally stronger current 411 intensity of 2.5 mA in the tDCS study). Interestingly, the present tRNS trial and Loo et al. 412 (2018) have used the highest total number of sessions and strongest stimulation parameters, 413 including current intensity, compared to other investigations of the antidepressant effects of 414 transcranial electrical stimulation (Blumberger et al., 2012; Loo et al., 2012a; Palm et al., 415 2012; Brunoni et al., 2013b; Bennabi et al., 2015), with both studies reporting no advantage 416 of active stimulation over sham.

417 The synaptic plasticity hypothesis of depression purports that MDD is characterized 418 by a partial reduction in long-term potentiation-like processes (Player et al., 2013; Kuhn et 419 al., 2016), suggesting that impaired synaptic plasticity, particularly in the prefrontal cortex, is 420 a key feature of the pathophysiology of depression (Goto et al., 2010; Duman et al., 2016; 421 Noda et al., 2018). This hypothesis is supported by evidence that the therapeutic efficacy of 422 antidepressants is, at least partly, due to their capacity to increase neural plasticity (Santarelli 423 et al., 2003; Castrén and Hen, 2013). Similarly, prior work from our group has demonstrated 424 that a course of tDCS increases neuroplasticity and mood outcomes in depression. However, 425 a correlation between these measures could not be confirmed due to the limited sample size (n = 18) (Player et al., 2014b). Despite a larger sample size from which to detect small effects 426 427 of the intervention, we did not see an increase in neuroplasticity levels following tRNS. 428 Previous research has shown that tRNS can induce acute neuroplastic after-effects, measured 429 by investigating changes to motor cortex excitability using TMS motor evoked potentials 430 (Terney et al., 2008; Chaieb et al., 2015; Ho et al., 2015a). However, there is no evidence to

date to suggest cumulative changes in neuroplasticity following a course of multiple repeated
sessions of tRNS, as assessed in this study. An important caveat to our results is that only a
subset of participants (44/69) completed the PAS study. It is theoretically possible that the
subset of participants who underwent the PAS protocol had different clinical, physiological,
or behavioural characteristics (e.g. greater levels of motivation) and may thus not be
representative of the larger sample.

437 The exact purported mechanisms of action for prolonged cortical excitation following 438 tRNS are unclear, but may include either 1) temporal summation of neural activity when 439 random noise stimuli and ongoing endogenous neuronal activity occur in close succession (Fertonani et al., 2011), and/or 2) enhancement of neuronal signalling via the principle of 440 441 stochastic resonance (van der Groen and Wenderoth, 2017). The latter refers to signals that 442 are too weak to exceed a threshold being amplified by adding a random noise stumulus, 443 improving the signal-to-noise ratio and the synchronization and coherence of neuronal 444 networks (Moss et al., 2004; Pavan et al., 2019). Though more research is required to 445 determine which of these mechanisms dominates, the action of tRNS appears to rely heavily 446 on detection and propagation of weak ongoing endogenous neuronal signals. The notion of 447 stochastic resonance has been demonstrated in several tRNS experiments aimed at enhancing 448 sensitivity to sensory inputs, including visual, auditory, and tactile stimuli (van der Groen and 449 Wenderoth, 2017). Interestingly, investigations of auditory (Rufener et al., 2017) and visual 450 (Van der Groen et al., 2018) perceptual thresholds have shown that tRNS has its largest effect 451 on near-threshold stimuli, whereas stimuli clearly above and below threshold were 452 unaffected. It may be for this reason that the only positive randomized control trials using 453 tRNS in clinical populations have stimulated the sensory and motor cortices, specifically in 454 the treatment of tinnitus via the auditory cortex (Vanneste et al., 2013), or stimulation of the 455 motor cortex for chronic pain in fibromyalgia (Curatolo et al., 2017). tRNS may restore the

456 dysfunctional activity in these cortical structures by normalizing their capacity to filter weak 457 signals amidst background neural noise. In complex disorders such as depression, however, it 458 is unclear what the depressed 'signal' might be. Studies seeking to use tRNS for other 459 complex disorders by stimulating prefrontal cortical regions have also reported negative 460 findings, i.e. for the treatment of multiple sclerosis (Palm et al., 2016b), and vegetative state 461 (Mancuso et al., 2017). Similarly to depression, these illnesses do not consist of a well-462 defined neural signal whose signalling properties can be augmented by tRNS to revert 463 pathophysiological dysfunctions of brain activity.

464 Although the present study reports null findings for the use of tRNS in depression, it provides valuable information regarding the safety and tolerability of multiple repeated 465 466 sessions of tRNS. To the best of our knowledge, the previous longest delivery of tRNS was 467 15 sessions (Chan et al., 2012), whereas participants in the current study experienced up to 40 468 sessions over eight weeks if allocated to the active tRNS condition. Adverse events of 469 erythema and paraesthesia were reported more frequently in the active tRNS condition as 470 compared to sham. These results are comparable to those observed in the tDCS literature, in which meta-analyses similarly suggest a greater frequency of erythema and paraesthesia 471 472 (Moffa et al., 2017; Nikolin et al., 2018). Of interest, fatigue and dizziness/light-headedness 473 were also noted more frequently during active tRNS sessions. These side effects are not a 474 common adverse effect of tDCS and might be unique to the tRNS stimulation parameters 475 used in the current study, for example, due to the current intensity ranging as high as 3 mA (2 476 mA direct offset with ±1 mA amplitude fluctuation). Importantly, fatigue and dizziness/light-477 headedness occurred rarely, in only 9.2% of sessions for fatigue, and 4.8% for light-478 headedness. Additionally, these adverse events were transient, resolved on their own shortly 479 after cessation of stimulation, and were not reported to be severe in intensity.

480 A limitation of the present study is that blinding was not preserved, possibly due to 481 the increased incidence of adverse events during active tRNS compared to sham. One would 482 expect inadequate blinding to reduce placebo effects for participants in the sham condition, 483 and potentially enhance them for participants receiving active tRNS, thereby increasing the 484 likelihood of observing a difference between groups. This was not the case in the present 485 study. Indeed, scores for mood outcomes were quantitatively (but not significantly) better in 486 the sham condition compared to active tRNS, suggesting that inadequate blinding did not bias 487 results in favour of the active treatment. Future studies may consider alternative methods to 488 adequately blind participants, including the use of a topical salve beneath the site of 489 stimulation to reduce paraesthetic effects and erythema (McFadden et al., 2011; Guarienti et 490 al., 2015), or comparisons against an active control condition (Fonteneau et al., 2019). 491 A major strength of the present study is the research design, which included double 492 blinding of participants and raters, examination of mood outcomes in addition to 493 neuroplasticity changes, comprehensive assessment of adverse events using 494 neuropsychological and physical measures, reporting of long-term follow-up outcomes up to 9-months following completion of the open-label phase, and rigorous statistical analysis 495 496 methodology informed by CONSORT guidelines.

497

# 498 **Conclusion**

This study represents the first randomised control trial for the use of tRNS to treat depression. Our findings do not lend support for the use of tRNS as a therapeutic intervention for depression. Antidepressant response was similar between active and sham tRNS conditions. tRNS did not increase motor cortical excitability, a measure of neuroplasticity associated with antidepressant response in other successful therapeutic clinical trials of

504	depression (Santarelli et al., 2003; Castrén and Hen, 2013). The profile of adverse events for
505	tRNS was similar to that of tDCS, with a significantly greater likelihood of erythema and
506	paraesthesia in the active tRNS condition, in addition to a higher incidence rate of fatigue and
507	dizziness/light-headedness. Participant blinding was not preserved and may be related to the
508	increased frequency of side effects in the active condition. Overall, the treatment was well-
509	tolerated by participants.
510	

# 511 Acknowledgements

512 This study was funded by a National Health and Medical Research Council

513 (NHMRC) Project Grant: APP1051423.

514

# 515 Statement of Interest

516 CL has served on a Janssen Advisory Board for Janssen and received an honorarium

517 from Mecta for teaching at an international electroconvulsive therapy (ECT) course. The

518 remaining authors have no conflicts of interest to declare.

# 520 **References**

521	Abe T, Miyaguchi S, Otsuru N, Onishi H (2019) The effect of transcranial random noise stimulation on
522	corticospinal excitability and motor performance. Neuroscience letters 705:138-142.
523	Ambrus GG, Paulus W, Antal A (2010) Cutaneous perception thresholds of electrical stimulation
524	methods: comparison of tDCS and tRNS. Clinical neurophysiology : official journal of the
525	International Federation of Clinical Neurophysiology 121:1908-1914.
526	Beck AT, Steer RA, Brown GK (1996) Manual for Beck Depression Inventory-II. San Antonio, TX: The
527	Psychological Corporation.
528	Bennabi D, Nicolier M, Monnin J, Tio G, Pazart L, Vandel P, Haffen E (2015) Pilot study of feasibility of
529	the effect of treatment with tDCS in patients suffering from treatment-resistant depression
530	treated with escitalopram. Clinical neurophysiology 126:1185-1189.
531	Bikson M et al. (2016) Safety of Transcranial Direct Current Stimulation: Evidence Based Update
532	2016. Brain Stimulation 9:641-661.
533	Blumberger D, Tran L, Fitzgerald P, Hoy KB, Daskalakis ZJ (2012) A randomized double-blind sham-
534	controlled study of transcranial direct current stimulation for treatment-resistant major
535	depression. Frontiers in psychiatry 3:74.
536	Broadbent DE, Cooper PF, FitzGerald P, Parkes KR (1982) The Cognitive Failures Questionnaire (CFQ)
537	and its correlates. Br J Clin Psychol 21:1-16.
538	Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F (2011) A systematic review on
539	reporting and assessment of adverse effects associated with transcranial direct current
540	stimulation. International Journal of Neuropsychopharmacology 14:1133-1145.
541	Brunoni AR, Ferrucci R, Bortolomasi M, Scelzo E, Boggio PS, Fregni F, Dell'Osso B, Giacopuzzi M,
542	Altamura AC, Priori A (2013a) Interactions between transcranial direct current stimulation
543	(tDCS) and pharmacological interventions in the Major Depressive Episode: findings from a
544	naturalistic study. Eur Psychiatry 28:356-361.
545	Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA,
546	Bensenor IM, Fregni F (2013b) The sertraline vs electrical current therapy for treating
547	depression clinical study: results from a factorial, randomized, controlled trial. JAMA
548	psychiatry 70:383-391.
549	Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA,
550	Bensenor IM, Fregni F (2013c) The sertraline vs. electrical current therapy for treating
551	depression clinical study: results from a factorial, randomized, controlled trial. JAMA
552	Psychiatry 70:383-391.
553	Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP,
554	Nogueira BS, Aparicio LV, Razza LB (2017) Trial of electrical direct-current therapy versus
555	escitalopram for depression. New England Journal of Medicine 376:2523-2533.
556	Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D,
557 558	Haffen E, Alonzo A, Loo CK (2016) Transcranial direct current stimulation for acute major
558 559	depressive episodes: meta-analysis of individual patient data. Br J Psychiatry 208:522-531. Castrén E, Hen R (2013) Neuronal plasticity and antidepressant actions. Trends in neurosciences
560	36:259-267.
561	Chaieb L, Antal A, Paulus W (2015) Transcranial random noise stimulation-induced plasticity is
562	NMDA-receptor independent but sodium-channel blocker and benzodiazepines sensitive.
563	Frontiers in neuroscience 9:125-125.
565 564	Chan HN, Alonzo A, Martin DM, Player M, Mitchell PB, Sachdev P, Loo CK (2012) Treatment of major
565	depressive disorder by transcranial random noise stimulation: case report of a novel
566	treatment. Biological psychiatry 72:e9-e10.
567	Contemori G, Trotter Y, Cottereau BR, Maniglia M (2019) tRNS boosts perceptual learning in
568	peripheral vision. Neuropsychologia 125:129-136.
200	

569 Curatolo M, La GB, Cosentino G, Baschi R, Salemi G, Talotta R, Romano M, Triolo G, De MT, Fierro B 570 (2017) Motor cortex tRNS improves pain, affective and cognitive impairment in patients with 571 fibromyalgia: preliminary results of a randomised sham-controlled trial. Clinical and 572 experimental rheumatology 35:100-105. 573 Delis DC, Kaplan E, Kramer JH (2001) Delis-Kaplan Executive Function System (D-KEFS). San Antonio, 574 TX: The Psychological Corporation. 575 Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California Verbal Learning Test (2nd ed.). San Antonio, 576 TX: The Psychological Corporation. 577 Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new 578 insights from stress and rapid-acting antidepressants. Nature medicine 22:238. 579 Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction 580 Questionnaire: a new measure. Psychopharmacol Bull 29:321-326. 581 Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ (2009) A 582 multidimensional tool to quantify treatment resistance in depression: the Maudsley staging 583 method. The Journal of clinical psychiatry 70:177-184. 584 Fertonani A, Pirulli C, Miniussi C (2011) Random noise stimulation improves neuroplasticity in 585 perceptual learning. The Journal of neuroscience : the official journal of the Society for 586 Neuroscience 31:15416-15423. 587 Fonteneau C, Mondino M, Arns M, Baeken C, Bikson M, Brunoni AR, Burke MJ, Neuvonen T, Padberg 588 F, Pascual-Leone A (2019) Sham tDCS: A hidden source of variability? Reflections for further 589 blinded, controlled trials. Brain stimulation. 590 Ghin F, Pavan A, Contillo A, Mather G (2018) The effects of high-frequency transcranial random noise 591 stimulation (hf-tRNS) on global motion processing: An equivalent noise approach. Brain 592 Stimul 11:1263-1275. 593 Goto Y, Yang CR, Otani S (2010) Functional and dysfunctional synaptic plasticity in prefrontal cortex: 594 roles in psychiatric disorders. Biological psychiatry 67:199-207. 595 Guarienti F, Caumo W, Shiozawa P, Cordeiro Q, Boggio PS, Benseñor IM, Lotufo PA, Bikson M, 596 Brunoni AR (2015) Reducing transcranial direct current stimulation-induced erythema with 597 skin pretreatment: considerations for sham-controlled clinical trials. Neuromodulation: 598 Technology at the Neural Interface 18:261-265. 599 Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD.: U.S. Department 600 of Health, Education, and Welfare. 601 Haesebaert F, Mondino M, Saoud M, Poulet E, Brunelin J (2014) Efficacy and safety of fronto-602 temporal transcranial random noise stimulation (tRNS) in drug-free patients with 603 schizophrenia: a case study. Schizophrenia research 159:251-252. 604 Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015) Response of depression to 605 electroconvulsive therapy: a meta-analysis of clinical predictors. The Journal of clinical 606 psychiatry 76:1374-1384. 607 Hayward KS, Brauer SG, Ruddy KL, Lloyd D, Carson RG (2017) Repetitive reaching training combined 608 with transcranial Random Noise Stimulation in stroke survivors with chronic and severe arm 609 paresis is feasible: a pilot, triple-blind, randomised case series. Journal of neuroengineering 610 and rehabilitation 14:46. 611 Ho K-A, Taylor JL, Loo CK (2015a) Comparison of the effects of transcranial random noise stimulation 612 and transcranial direct current stimulation on motor cortical excitability. The journal of ECT 613 31:67-72. 614 Ho KA, Taylor JL, Loo CK (2015b) Comparison of the effects of transcranial random noise stimulation 615 and transcranial direct current stimulation on motor cortical excitability. The journal of ECT 616 31:67-72. 617 Inukai Y, Saito K, Sasaki R, Tsuiki S, Miyaguchi S, Kojima S, Masaki M, Otsuru N, Onishi H (2016) 618 Comparison of Three Non-Invasive Transcranial Electrical Stimulation Methods for Increasing 619 Cortical Excitability. Front Hum Neurosci 10:668-668.

620 Jooss A, Haberbosch L, Kohn A, Ronnefarth M, Bathe-Peters R, Kozarzewski L, Fleischmann R, Scholz 621 M, Schmidt S, Brandt SA (2019) Motor Task-Dependent Dissociated Effects of Transcranial 622 Random Noise Stimulation in a Finger-Tapping Task Versus a Go/No-Go Task on Corticospinal 623 Excitability and Task Performance. Frontiers in neuroscience 13:161. 624 Kreuzer PM, Vielsmeier V, Poeppl TB, Langguth B (2017) A Case Report on Red Ear Syndrome with 625 Tinnitus Successfully Treated with Transcranial Random Noise Stimulation. Pain physician 626 20:E199-e205. 627 Kuhn M, Mainberger F, Feige B, Maier JG, Mall V, Jung NH, Reis J, Klöppel S, Normann C, Nissen C 628 (2016) State-dependent partial occlusion of cortical LTP-like plasticity in major depression. 629 Neuropsychopharmacology 41:1521. 630 Liu W, Ge T, Leng Y, Pan Z, Fan J, Yang W, Cui R (2017) The Role of Neural Plasticity in Depression: 631 From Hippocampus to Prefrontal Cortex. Neural Plast 2017:6871089. 632 Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012a) Transcranial direct current 633 stimulation for depression: 3-week, randomised, sham-controlled trial. The British Journal of 634 Psychiatry 200:52-59. 635 Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012b) Transcranial direct current 636 stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry 637 200:52-59. 638 Loo CK, Sachdev P, Martin D, Pigot M, Alonzo A, Malhi GS, Lagopoulos J, Mitchell P (2010) A double-639 blind, sham-controlled trial of transcranial direct current stimulation for the treatment of 640 depression. Int J Neuropsychopharmacol 13:61-69. 641 Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM, 642 McClintock SM, Mohan A (2018) International randomized-controlled trial of transcranial 643 Direct Current Stimulation in depression. Brain Stimulation: Basic, Translational, and Clinical 644 Research in Neuromodulation 11:125-133. 645 Mammarella N, Di Domenico A, Palumbo R, Fairfield B (2017) Self-generation and positivity effects 646 following transcranial random noise stimulation in medial prefrontal cortex: A reality 647 monitoring task in older adults. Cortex; a journal devoted to the study of the nervous system 648 and behavior 91:186-196. 649 Mancuso M, Abbruzzese L, Canova S, Landi G, Rossi S, Santarnecchi E (2017) Transcranial random 650 noise stimulation does not improve behavioral and neurophysiological measures in patients 651 with subacute vegetative-unresponsive wakefulness state (VS-UWS). Frontiers in human 652 neuroscience 11:524. 653 McFadden JL, Borckardt JJ, George MS, Beam W (2011) Reducing procedural pain and discomfort 654 associated with transcranial direct current stimulation. Brain stimulation 4:38-42. 655 Moffa AH, Brunoni AR, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D, 656 Haffen E, Alonzo A (2017) Safety and acceptability of transcranial direct current stimulation 657 for the acute treatment of major depressive episodes: Analysis of individual patient data. 658 Journal of affective disorders 221:1-5. 659 Moliadze V, Fritzsche G, Antal A (2014) Comparing the efficacy of excitatory transcranial stimulation 660 methods measuring motor evoked potentials. Neural Plast 2014:837141-837141. 661 Montagne B, Kessels RP, De Haan EH, Perrett DI (2007) The Emotion Recognition Task: a paradigm to 662 measure the perception of facial emotional expressions at different intensities. Perceptual 663 and motor skills 104:589-598. 664 Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J 665 Psychiatry 134:382-389. 666 Moss F, Ward LM, Sannita WG (2004) Stochastic resonance and sensory information processing: a 667 tutorial and review of application. Clinical neurophysiology : official journal of the 668 International Federation of Clinical Neurophysiology 115:267-281. 669 Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY (2018) Efficacy and acceptability of non-invasive brain 670 stimulation for the treatment of adult unipolar and bipolar depression: A systematic review

671	and meta-analysis of randomised sham-controlled trials. Neuroscience and biobehavioral
672	reviews 92:291-303.
673	Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK (2017) Safety of repeated sessions of transcranial
674	direct current stimulation: A systematic review. Brain Stimulation.
675	Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK (2018) Safety of repeated sessions of transcranial
676	direct current stimulation: A systematic review. Brain Stimulation: Basic, Translational, and
677	Clinical Research in Neuromodulation 11:278-288.
678	Nitsche M, Paulus W (2001) Sustained excitability elevations induced by transcranial DC motor
679	cortex stimulation in humans. Neurology 57:1899-1901.
680	Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, Paulus W, Hummel F, Boggio PS,
681	Fregni F, Pascual-Leone A (2008) Transcranial direct current stimulation: State of the art
682	2008. Brain Stimul 1:206-223.
683	Noda Y, Zomorrodi R, Vila-Rodriguez F, Downar J, Farzan F, Cash RF, Rajji TK, Daskalakis ZJ,
684	Blumberger DM (2018) Impaired neuroplasticity in the prefrontal cortex in depression
685	indexed through paired associative stimulation. Depression and anxiety 35:448-456.
686	Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E, Pogarell O, Nitsche M, Möller H-J,
687	Padberg F (2012) Transcranial direct current stimulation in treatment resistant depression: a
688	randomized double-blind, placebo-controlled study. Brain stimulation 5:242-251.
689	Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, Dimitri D, Creange A, Lefaucheur JP,
690	Ayache SS (2016a) Effects of transcranial random noise stimulation (tRNS) on affect, pain
691	and attention in multiple sclerosis. Restorative neurology and neuroscience 34:189-199.
692	Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, Dimitri D, Créange A, Lefaucheur J-P,
693	Ayache SS (2016b) Effects of transcranial random noise stimulation (tRNS) on affect, pain
694	and attention in multiple sclerosis. Restorative neurology and neuroscience 34:189-199.
695	Pavan A, Ghin F, Contillo A, Milesi C, Campana G, Mather G (2019) Modulatory mechanisms
696	underlying high-frequency transcranial random noise stimulation (hf-tRNS): A combined
697	stochastic resonance and equivalent noise approach. Brain Stimul.
698	Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms.
699	Neuropsychopharmacology : official publication of the American College of
700	Neuropsychopharmacology 33:88-109.
701	Player MJ, Taylor JL, Alonzo A, Loo CK (2012) Paired associative stimulation increases motor cortex
702	excitability more effectively than theta-burst stimulation. Clinical neurophysiology : official
703	journal of the International Federation of Clinical Neurophysiology 123:2220-2226.
704	Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev P, Martin D, Mitchell PB, Loo CK (2013)
705	Neuroplasticity in depressed individuals compared with healthy controls.
706	Neuropsychopharmacology 38:2101.
707	Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev PS, Martin D, Mitchell PB, Loo CK (2014a)
708	Increase in PAS-induced neuroplasticity after a treatment course of transcranial direct
709	current stimulation for depression. J Affect Disord 167:140-147.
710	Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev PS, Martin D, Mitchell PB, Loo CK (2014b)
711	Increase in PAS-induced neuroplasticity after a treatment courseof transcranial direct
712	current stimulation for depression. Journal of affective disorders 167:140-147.
713	Popescu T, Krause B, Terhune DB, Twose O, Page T, Humphreys G, Cohen Kadosh R (2016)
714	Transcranial random noise stimulation mitigates increased difficulty in an arithmetic learning
715	task. Neuropsychologia 81:255-264.
716	Rufener KS, Ruhnau P, Heinze H-J, Zaehle T (2017) Transcranial random noise stimulation (tRNS)
717	shapes the processing of rapidly changing auditory information. Frontiers in cellular
718	neuroscience 11:162.
719	Rufener KS, Geyer U, Janitzky K, Heinze HJ, Zaehle T (2018) Modulating auditory selective attention
720	by non-invasive brain stimulation: Differential effects of transcutaneous vagal nerve

<b>50</b> 1	
721	stimulation and transcranial random noise stimulation. The European journal of
722	neuroscience 48:2301-2309.
723	Ruff RM, Allen CC (1996) Ruff 2 and 7 Selective Attention Test Professional Manual. Odessa, FL:
724	Psychological Assessment Resources, Inc.
725	Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME,
726	Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M
727	(2006) Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several
728	Treatment Steps: A STAR*D Report. Am J Psychiatry 163:1905-1917.
729	Salemi G, Vazzoler G, Ragonese P, Bianchi A, Cosentino G, Croce G, Gangitano M, Portera E,
730	Realmuto S, Fierro B, Brighina F (2019) Application of tRNS to improve multiple sclerosis
731	fatigue: a pilot, single-blind, sham-controlled study. Journal of neural transmission (Vienna,
732	Austria : 1996).
733	Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O
734	(2003) Requirement of hippocampal neurogenesis for the behavioral effects of
735	antidepressants. science 301:805-809.
736	Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting
737	parallel group randomised trials. BMC medicine 8:18.
738	Shalev N, De Wandel L, Dockree P, Demeyere N, Chechlacz M (2018) Beyond time and space: The
739	effect of a lateralized sustained attention task and brain stimulation on spatial and selective
740	attention. Cortex; a journal devoted to the study of the nervous system and behavior
741	107:131-147.
742	Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC
743	(1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and
744	validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The
745	Journal of clinical psychiatry 59 Suppl 20:22-33;quiz 34-57.
746	Smith A (1991) Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services.
747	Snowball A, Tachtsidis I, Popescu T, Thompson J, Delazer M, Zamarian L, Zhu T, Kadosh RC (2013)
748	Long-term enhancement of brain function and cognition using cognitive training and brain
749	stimulation. Current Biology 23:987-992.
750	Stefan K, Wycislo M, Classen J (2004) Modulation of associative human motor cortical plasticity by
751	attention. Journal of neurophysiology 92:66-72.
752	Szymkowicz SM, McLaren ME, Suryadevara U, Woods AJ (2016) Transcranial Direct Current
753	Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review. Psychiatric
754	annals 46:642-646.
755	Terney D, Chaieb L, Moliadze V, Antal A, Paulus W (2008) Increasing human brain excitability by
756	transcranial high-frequency random noise stimulation. Journal of Neuroscience 28:14147-
757	14155.
758	Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH,
759	Lebowitz B, McGrath PJ (2006) Evaluation of outcomes with citalopram for depression using
760	measurement-based care in STAR* D: implications for clinical practice. American journal of
761	Psychiatry 163:28-40.
762	Tyler SC, Conto F, Battelli L (2018) Rapid Improvement on a Temporal Attention Task within a Single
763	Session of High-frequency Transcranial Random Noise Stimulation. Journal of cognitive
764	neuroscience 30:656-666.
765	van der Groen O, Wenderoth N (2017) Random noise stimulation of the cortex: stochastic resonance
766	enhances central mechanisms of perception. Brain Stimulation: Basic, Translational, and
767	Clinical Research in Neuromodulation 10:e4.
768	Van der Groen O, Tang MF, Wenderoth N, Mattingley JB (2018) Stochastic resonance enhances the
769	rate of evidence accumulation during combined brain stimulation and perceptual decision-
770	making. PLoS computational biology 14:e1006301.

- 771 Vanneste S, Fregni F, De Ridder D (2013) Head-to-head comparison of transcranial random noise
- stimulation, transcranial AC stimulation, and transcranial DC stimulation for tinnitus.
  Frontiers in psychiatry 4:158.
- 774 Wechsler D (2008) Wechsler Adult Intelligence Scale (4th ed.). San Antonio, TX: Pearson.

# 776 Supplementary Materials

### 777 Paired associative stimulation methods

778 Participants sat in a comfortable, relaxed position with both hands on a pillow. The optimal site for eliciting motor evoked potentials (MEPs) in the right first dorsal interosseous 779 780 (FDI) muscle was first established and marked on the scalp. Each participant's resting motor 781 threshold (RMT) – defined as the minimum stimulus intensity to evoke MEPs of  $\geq 50 \,\mu\text{V}$  in 782 the relaxed FDI in 5 out of 10 consecutive trials of single-pulse TMS – was then measured. 783 TMS intensity for evoking test MEPs was adjusted individually for each participant to elicit 784 an average 1 mV response. TMS intensity for testing MEPs was limited to a maximum of 130% of RMT even if the actual intensity needed to elicit a 1 mV response was greater. 785 786 For the stimulation protocol, single-pulse TMS (130% of RMT) to the FDI 787 representation on the left motor cortex was combined with electrical stimuli (200 µs duration, 300% perceptual threshold, DS7 stimulator; Digitimer Co. Ltd., Hertfordshire, UK) to the 788 789 right ulnar nerve proximal to the wrist. Two hundred pairs of stimuli (TMS and ulnar nerve) 790 were given at 0.25 Hz over  $\sim$ 13 minutes. In each pair, ulnar nerve stimulation preceded TMS 791 by 25 ms. Electrical stimuli were delivered occasionally to the right index finger during PAS. 792 Participants counted the stimuli and reported the number at the end of the session to ensure sensory attention to the hand (Stefan et al., 2004). The MEPs recorded before and after PAS 793 794 to assess cortical excitability consisted of testing blocks of 20 MEPs at a rate of 0.1 Hz. Two 795 blocks of MEPs were recorded at baseline. A block of MEPs was recorded immediately after 796 PAS and then every 10 mins for one hour. During all stimulation, EMG from the FDI was 797 monitored to ensure muscle relaxation. MEPs were discarded if EMG showed substantial 798 muscle activity (i.e. peak-to-peak amplitude  $\geq 50 \,\mu\text{V}$ ) in the time window prior to the TMS 799 stimuli. Additionally, block-averaged MEP amplitudes were considered outliers if they were

- 800 more than 4 standard deviations from the mean for active and sham tRNS conditions
- 801 combined.
- 802 EMG activity was recorded through Ag/AgCl surface electrodes over the right FDI. EMG
- 803 was amplified, bandpass filtered (16–1000 Hz), and digitized (2000 Hz) (Cambridge
- 804 Electronics Design, Cambridge, UK). TMS (Magstim 200 stimulator, Magstim Co.,
- 805 Whitland, UK) was applied using a 70-mm figure-of eight coil oriented with the handle
- 806 posterolateral, 45° to the parasagittal plane.

Week	Baseline Wk 0	Sham-controlled phase				Open-label phase				Taper phase				
		Wk 1	Wk 2	Wk 3	Wk 4	Wk 1	Wk 2	Wk 3	Wk 4	Wk 1	Wk 2	Wk 3	Wk 4	
Session	Pre 1	1-5	6-10	11-15	16-20	21-25	26-30	31-35	36-40	41	42	43	44	
Mood Assessments														
MADRS	Х		Х		Х		Х		Х				Х	
BDI-II	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	
CGI-S	Х													
CGI-I			Х		Х		Х		Х				Х	
Q-LES-SF	Х				Х				Х				Х	
Neurophysiological Assessments														
PAS	Х				Х				Х					
Neuropsychological Assessments														
CVLT-II	Х				Х				Х					
Ruff 2 & 7	Х				Х				Х					
WAIS-IV Digit Span	Х				Х				Х					
SDMT	Х				Х				Х					
D-KEFS Verbal Fluency	Х				Х				Х					
CFO	Х				Х				Х					

### 807 Supplementary Table S1. Schedule of assessments.

808 809 810 Wk: Week. MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale

ranked from 1-normal to 7-extremely ill. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse. Q-

LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form. PAS: Paired associative stimulation. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult

811 Intelligence Scale. SDMT: Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire

# 812 Supplementary Table S2. Intention-to-treat analyses.

- 813 Estimated marginal means and results from MERM analyses during the sham-controlled phase, including the following covariates: Maudsley
- 814 staging parameters total score as a measure of treatment resistance, and antidepressant use. Mood, quality of life, neuroplasticity, and
- 815 neuropsychological outcome measures are reported using an intention-to-treat analysis approach.

	Baseline		Week 2		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	Sham	Active	F	р	F	р	F	р
Mood Assessments (m, SEM)												
MADRS	29.1 (0.8)	29.0 (0.8)	24.4 (1.0)	24.8 (1.1)	22.1 (1.2)	23.7 (1.3)	0.29	0.593	43.09	<0.001	0.77	0.467
BDI-II	32.4 (1.6)	33.4 (1.7)	24.9 (1.9)	27.1 (2.0)	21.9 (1.9)	25.1 (2.0)	1.07	0.306	25.07	<0.001	0.58	0.678
CGI-I	-	-	3.5 (0.1)	3.6 (0.1)	3.1 (0.1)	3.4 (0.1)	2.60	0.112	13.07	<0.001	1.98	0.165
Q-LES-SF	32.5 (1.8)	35.8 (2.0)	-	-	43.6 (2.8)	43.8 (2.9)	0.37	0.545	32.00	<0.001	0.80	0.376
Neuroplasticity Assessments (m, SEM)												
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	-	-	1.31 (0.09)	1.40 (0.10)	0.08	0.780	1.63	0.209	0.33	0.570
Neuropsychological Assessments (m, SEM)												
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.2)	48.8 (2.2)	-	-	46.3 (2.3)	49.7 (2.1)	2.29	0.133	0.10	0.751	0.01	0.943
CVLT-II: Long delay free recall z-score	-0.42 (0.21)	0.03 (0.21)	-	-	-0.64 (0.22)	-0.39 (0.21)	2.82	0.096	1.93	0.167	0.23	0.635
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.6 (0.7)	-	-	10.9 (0.7)	11.9 (0.7)	1.18	0.280	0.00	0.991	0.21	0.648
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	-	-	9.9 (0.8)	11.7 (0.8)	1.64	0.204	0.07	0.789	1.78	0.187
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.2 (0.6)	-	-	9.6 (0.6)	10.6 (0.6)	3.61	0.060	0.56	0.454	0.04	0.850
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	50.6 (1.9)	-	-	51.4 (1.9)	53.6 (1.9)	2.17	0.144	2.97	0.087	0.07	0.789
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.5 (2.3)	-	-	50.4 (2.4)	48.7 (2.3)	1.07	0.302	0.36	0.547	0.09	0.764
SDMT: Total correct z-score	-0.31 (0.17)	0.22 (0.18)	-	-	0.00 (0.18)	0.40 (0.17)	4.10	0.047	4.38	0.039	0.53	0.469
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.5)	-	-	10.5 (0.6)	12.6 (0.5)	13.67	<0.001	2.50	0.116	0.09	0.771

CFQ: Total score 50.1 (2.2) 46.6 (2.2) 49.9 (2.3) 50.0 (2.2) 0.435 0.61 0.45 0.501 0.70 0.406 --

816 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale ranked

817 from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form. PAS: Paired associative stimulation. MEP: motor

818 819 evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System.

CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measures

#### Supplementary Table S3. MADRS mixed-effects repeated measures analyses 820

- using other covariates. 821
- 822 Results from MERM analyses during the sham-controlled phase to examine the impact of
- 823 medications and treatment expectations as covariates on mood outcomes (i.e. MADRS
- 824 scores).

	Covariate		Time		Condition		Time x Condition	
	F	р	F	р	F	р	F	р
Baseline TEQ	0.28	0.599	40.93	<0.001	0.99	0.325	1.32	0.276
Antidepressants	1.14	0.289	44.28	<0.001	2.03	0.160	1.11	0.335
Lithium	3.73	0.058	44.20	<0.001	2.24	0.140	1.14	0.327
Benzodiazepine*	2.48	0.120	44.24	<0.001	1.88	0.175	1.12	0.332
Antipsychotics	1.78	0.188	44.22	<0.001	2.15	0.147	1.12	0.332
Anticonvulsants	0.34	0.561	44.26	<0.001	2.10	0.152	1.12	0.332

825 826 \*Participants were required to cease benzodiazepine medication use prior to commencing the trial.

TEQ: Treatment Expectations Questionnaire

### 827 Supplementary Table S4. Mood, quality of life, neuroplasticity and

### 828 neuropsychological outcome measures.

- 829 Results from MERM analyses during the acute daily treatment phases combined (i.e. tRNS
- 830 received during the sham-controlled and open-label phases).

	Con	Condition		Time		Time × Condition	
	F	р	F	р	F	р	
Mood Assessments (m, SEM)							
MADRS	1.09	0.300	29.39	<0.001	0.75	0.560	
BDI-II	2.38	0.128	17.60	<0.001	1.00	0.447	
CGI-I	6.02	0.017	15.84	<0.001	1.72	0.173	
Q-LES-SF	0.00	0.967	30.00	<0.001	1.39	0.257	
Neuroplasticity Assessments (m, SEM)							
PAS: MEP amplitude	0.40	0.530	2.11	0.135	0.72	0.193	
Neuropsychological Assessments (m, SEM)							
CVLT-II: Trial 1-5 total recall t-score	4.47	0.036	3.12	0.046	0.17	0.844	
CVLT-II: Long delay free recall z-score	5.40	0.021	3.03	0.051	0.23	0.799	
D-KEFS: Letter fluency scaled score	2.70	0.102	0.14	0.867	0.38	0.683	
D-KEFS: Category fluency scaled score	1.97	0.165	0.74	0.477	1.69	0.190	
D-KEFS: Category switching total scaled score	2.94	0.088	1.07	0.346	0.24	0.786	
Ruff 2 & 7: Total speed t-score	2.94	0.088	3.50	0.032	0.06	0.946	
Ruff 2 & 7: Total accuracy t-score	0.80	0.372	0.73	0.482	0.22	0.805	
SDMT: Total correct z-score	3.58	0.063	2.80	0.065	1.11	0.335	
WAIS-IV Digit Span: Total correct scaled score	17.17	<0.001	2.05	0.132	0.06	0.945	
CFQ: Total score	0.20	0.659	0.12	0.891	0.45	0.639	

831 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global

832 Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse.

833 Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation.

834 MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT:

835 Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire.

836 m: Mean. SEM: Standard error of measures

# 837 Supplementary Figure S1. Treatment Expectations Questionnaire

Treatment Expectations Questionnaire – Views on DCS								
Participant ID	Date	Sess	ion					
improve some sy	e following question rmptoms of depress symptom, please c	sion you may be e						
1) How effectiv	e do you think DC	S will be for <u>imp</u>	oving your sleep?	•				
1	2	3	4	5	NA			
Not effective a all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with sleep			
2) How effectiv	e do you think DC	S will be for <u>redu</u>	cing feelings of sa	udness?				
1	2	3	4	5	NA			
Not effective a all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with feeling sad			
<b>3)</b> How effectiv	e do you think DC	S will be for <u>imp</u>	oving your <b>appet</b>	ite?				
1	2	3	4	5	NA			
Not effective as all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with			
					my appetite			
4) How effectiv making?	e do you think DC	S will be for <u>imp</u>	oving your <b>conce</b>	ntration/decisior	ı			
1	2	3	4	5	NA			
Not effective a all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with concentration/			
					decision making			

5) How effective do you think DCS will be for reducing thoughts of death or suicide?

1	2	3	4	5	NA	
Not effective a all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with	
					thoughts of death or suicide	
	ve do you think DC • <b>ability to enjoy th</b>		roving your genera	al interest in thi	ngs	
1	2	3	4	5	NA	
Not effective a all	t Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with general interest/ enjoying things	
7) How effectiv	ve do you think DC	S will be for <u>imp</u>	roving your <b>energ</b>	y level?		
1	2	3	4	5	NA	
Not effective at	t Only a little bit	Moderately	Quite Effective		I don't have	
all	Effective	Effective		Effective	problems with m energy levels	
	, how effective do y ou are currently exp		ill be for helping to	improve the		
1	2	3	4	5		
Not effective a all	at Only a little bit Effective	Moderately Effective	Quite Effect	ive Extremely Effective		
9) Are there an	y particular reasons	why you believe	DCS will or will i	not be effective?		

839

END OF QUESTIONNAIRE


#### Supplementary Figure S2. tRNS Side Effects Questionnaire 841

Side Effect	Before	During	After	Severity*	Causality <sup>#</sup>
Redness anode cathode					
Tingling/Itching/Burning/Pain anode cathode					
Nausea					
Lightheadedness/Dizziness					
Headache					
Blurred Vision					
Fatigue					
Other:					

\*Severity: 1 = Mild; 2 = Moderate; 3 = Severe. If participant had a side effect after the previous tRNS session, ask when it started and for how long and record in the 'Before' column. <sup>#</sup>Causality: 1 = Probably Related; 2 = Possibly Related; 3 = Probably Not Related; 4 = Not Related


### 843 Supplementary Figure S3. CONSORT flow diagram.

- 844 The study was registered at:
- 845 https://clinicaltrials.gov/ct2/show/NCT01792414 (ID: NCT01792414).





### 847 Supplementary Figure S4. Follow-up mood outcome measures.

- 848 Graphs showing mood and quality of life scores (unadjusted means  $\pm$  SD) from baseline up to
- the 9-month follow-up assessment following completion of the open-label phase. Sample
- sizes used for the calculation of summary statistics are presented for each time-point. A)
- 851 Montgomery-Asberg Depression Rating Scale (MADRS) scores. B) Beck Depression
- 852 Inventory (BDI-II) scores. C) Clinician Global Impression Severity (CGI-S) at baseline, and
- 853 CGI-Improvement (CGI-I) scores; the CGI-S is a 7-point clinician-rated scale ranked from 1-
- normal (not at all ill) to 7-among most extremely ill patients. The CGI-I is a 7-point clinician-
- rated scale ranked from 1-very much improved to 7-very much worse. **D)** Quality of Life
- 856 Enjoyment and Satisfaction Questionnaire Short Form scores (Q-LES-SF).


















### 862 Supplementary Figure S5. Paired associative stimulation.

Group data (estimated marginal means ± bootstrapped 95% confidence intervals) showing the
time course of changes in the amplitude of motor evoked potentials (MEPs) immediately
after the PAS conditioning stimulus. Post-PAS MEP amplitudes were normalized to pre-PAS
amplitudes for each participant. A) MEP amplitude changes at baseline, prior to the course of
tRNS. B) MEP amplitude changes following the 4-week sham-controlled phase.



## 869 Supplementary Figure S6. Correlation between mood and neuroplasticity.

- 870 There was no association between percent change in motor evoked potentials (MEPs)
- 871 following paired associative stimulation (PAS) and percent change in mood scores over the
- 872 course of the sham-controlled phase (r = -0.02, p = 0.905).



873 874